- Location
drug eluting stent
"-
Total Artificial Heart Might Be The Next Potential Medtech Goldmine
Sep 10, 2014It's too early to tell, but the total artificial heart might be the next potential medtech goldmine. Shares of artificial heart maker Carmat climbed nearly 20% in mid-day trading on September 5 amidst recently-confirmed rumors that the ...
Tags: Health, Medicine, Artificial hearts
-
The Project Has Been Awarded Euro 5.874M by The European Union
Jan 20, 2014As co-ordinator of the European project 'ReBioStent', Ceram, the international materials technology company, is pleased to announce that the project, to develop new biomaterials and new arterial stents, has been awarded Euro 5.874M by the ...
Tags: Construction, Decoration, Ceram-Lead Project
-
Robert B. Hance Will Join The Company as Chief Executive Officer in September 2013
Dec 20, 2013Creganna-Tactx Medical has announced today that Robert B. Hance will join the company as Chief Executive Officer in September 2013, taking over the role from Helen Ryan who has held the position for the last eight years. Robert ...
Tags: medicine, Creganna-Tactx Medical
-
Promus Premier Coronary Stent System Has Obtained an Approval From The US FDA
Nov 27, 2013US-based Boston Scientific has obtained an approval from the US Food and Drug Administration (FDA) for its Promus PREMIER everolimus-eluting platinum chromium coronary stent system. The company's next-generation durable polymer ...
-
Svelte Medical Had Completed Enrollment in Its DIRECT II Drug-Eluting Stent Clinical Study
Nov 22, 2013Svelte Medical Systems (New Providence, NJ) announced that it had successfully completed enrollment in its DIRECT II drug-eluting stent clinical study. The trial is designed to study the safety and efficacy of the company’s ...
Tags: Svelte Medical, Enrollment, DIRECT II
-
Medtronic Resolute Stent New Sizing Options Are Approved by FDA
Feb 27, 2013Medtronic has gained US marketing rights for new sizes of its Resolute Integrity drug-eluting stent, following the regulatory approval from the Food and Drug Administration (FDA). Available in 34mm, 38mm lengths and 3.0mm, 3.5mm and 4.0mm ...
-
New Polymer Drug-Eluting Stent System Will Be Launched by Boston Scientific Soon in Europe
Feb 19, 2013US-based medical technology provider Boston Scientific said it is launching the new polymer-based drug-eluting stent (DES) system in the European market as the product has obtained CE mark approval. The Promus Premier everolimus-eluting ...
-
Abbott Has Initiated a ABSORB III Clinical Trial of Its Drug Eluting BVS Device
Jan 10, 2013Abbott has initiated a ABSORB III clinical trial of its drug eluting bioresorbable vascular scaffold (BVS) device, designed for the treatment of coronary artery disease patients. The Absorb device, which includes a multi-link stent ...
Tags: Abbott, ABSORB III clinical trial, drug eluting BVS, treatment
-
First Patient Enrollment are Completed by Biosensors
Dec 19, 2012Biosensors International Group has completed enrolling the first patient in its polymer-free drug-coated stent's (DCS) clinical trial, designed to compare the safety of the BioFreedom with a bare-metal stent (BMS). Designed for use in ...
-
Boston Scientific Has Obtained CE Mark Approval for Its Synergy Bioabsorbable
Dec 18, 2012Boston Scientific has obtained CE mark approval for its Synergy Everolimus-Eluting platinum chromium coronary stent system, designed to improve post-implant vessel healing. The coronary stent, which features a combination of ...
-
Abbott's Everolimus Eluting Coronary Stent System Has Been Accorded with CE Mark
Dec 18, 2012Global healthcare firm Abbott's everolimus eluting coronary stent system has been accorded with CE Mark in Europe. The XIENCE Xpedition everolimus eluting coronary stent system, which is used to treat coronary artery disease, provides ...
Tags: Abbott, CE mark, coronary stent system, coronary artery disease
-
Tryton Medical Has Completed Enrolling Patients in The Pivotal Study
Nov 29, 2012Tryton Medical has completed enrolling patients in the pivotal study of its Tryton Side Branch Stent system, designed for treating bifurcation lesions. The CE-marked cobalt chromium stent uses a standard single-wire balloon-expandable ...
Tags: Tryton Medical, Tryton Side Branch Stent system, bifurcation lesions
-
Medtronic Has Presented Two Years of Follow-up Study Results of Its Resolute DES
May 28, 2012Medtronic has presented two years of follow-up study results of its Resolute drug-eluting stent (DES). The study, which enrolled 878 standard risk2 diabetes patients and 1,903 patients without diabetes, will compare the clinical ...
Related Products
-
High Quality Medical Cardiac Drug Eluting Coronary Stent
-
Medical Drug-Eluting Coronary Stent for CPI Cases
-
Medical Des Cardiovascular Drug Stent Sirolimus-Eluting Coronary Stent
-
Medical Drug Eluting Stent/Sirolimus-Eluting Coronary Stent System for Cardiac Surgery
-
Drug Eluting Stent System Placed Within The Peripheral Coronary Artery
-
Medical Des Cardiovascular Sirolimus-Eluting Drug Stent OEM Coronary Stent
